Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.39 |
| ▸ | HTR2A | P28223 | 6/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9093685 | 0.90 | HTR2C (0.37) | HTR2CHTR2AHDAC11HDAC8HDAC6 | |
| SCHEMBL9093453 | 0.88 | HTR2C (0.32) | HTR2CHTR2A | |
| SCHEMBL9091998 | 0.84 | HTR2C (0.56) | HTR2CHTR2APRMT5 | |
| SCHEMBL9094086 | 0.78 | HTR2C (0.34) | HTR2CHTR2A | |
| SCHEMBL9092789 | 0.76 | HTR7 (0.43) | HTR2CHTR2APRMT5 | |
| SCHEMBL7213160 | 0.72 | — | — | |
| SCHEMBL9441469 | 0.72 | — | — | |
| SCHEMBL9092925 | 0.70 | TUBB4A (0.43) | HTR2CHTR2A | |
| SCHEMBL9441397 | 0.68 | — | — | |
| SCHEMBL9095541 | 0.68 | EGFR (0.41) | HTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624302-B2 | Culturing immunosuppressants, neurotrophic agents, and macrolactone antibiotics; side effect reduction | KOSAN BIOSCIENCES, INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030144315-A1 | Novel polyketide derivatives | CHU DANIEL (US) | 2003-07-31 | — | — | US | disclosed |
| US-6569867-B2 | As drugs | KOSAN BIOSCIENCES, INC. | 2003-05-27 | — | — | US | disclosed |
| US-20020183348-A1 | For use as drugs | CHU DANIEL (US) | 2002-12-05 | — | — | US | disclosed |
| US-20020065295-A1 | Novel polyketide derivatives | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-05-30 | — | — | US | disclosed |
| EP-0532088-B1 | O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroaryl macrolides | MERCK & CO INC (US) | 1996-12-04 | — | — | EP | disclosed |
| US-5352783-A | Treating autoimmune diseases | MERCK & CO., INC. (US) | 1994-10-04 | — | — | US | disclosed |
| US-5349061-A | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity | MERCK & CO., INC. (US) | 1994-09-20 | — | — | US | disclosed |
| US-5310901-A | Autoimmune diseases; antiinflammatory agents; fungicides; prevention of organ transplant rejection; alkylation and/or arylation at C-42 | MERCK & CO., INC. (US) | 1994-05-10 | — | — | US | disclosed |
| US-5252732-A | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity | MERCK & CO., INC. (US) | 1993-10-12 | — | — | US | disclosed |
| WO-1993005058-A1 | O-HETEROARYL, O-ALKYLHETEROARYL, O-ALKENYLHETEROARYL AND O-ALKYNYLHETEROARYLMACROLIDES | MERCK & CO., INC. (US) | 1993-03-18 | — | — | WO | disclosed |
| EP-0532088-A1 | O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroaryl macrolides | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183348-A1 | For use as drugs | HSD17B14, CYP3A4, CYP3A5 | HTR2C 2436/4885HTR2A 3345/4885PRMT5 100/4885 |
| US-20030144315-A1 | Novel polyketide derivatives | HSD17B14, RIOX2, MRPL21 | HTR2C 3986/4885HTR2A 4270/4885PRMT5 193/4885 |
| US-20020065295-A1 | Novel polyketide derivatives | HSD17B14, RIOX2, MRPL21 | HTR2C 3986/4885HTR2A 4270/4885PRMT5 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.